Robert Kyler, MD
Radiation Oncology · Fishersville, VANPI 1396746715
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $653 of the $762 with a category attached, or 85.7%. It is spread thinly across 17 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $259 and has fallen 50.9% since, to $127 in 2025.
Across 31 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$154
- Lilly USA, LLC$101
- Merck$88
- Novocure Inc.$55
- Pfizer$53
- Amgen$50
- plus $261 from 11 others
What the payments were for
- Food & beverage$65386%
- Education$10914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $154 |
| Lilly USA, LLC | 2 | $101 |
| Merck | 3 | $88 |
| Novocure Inc. | 3 | $55 |
| Pfizer | 3 | $53 |
| Amgen | 3 | $50 |
| Novartis | 2 | $47 |
| AstraZeneca(2 entities) | 2 | $41 |
| Myovant Sciences Inc. | 2 | $32 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Sanofi | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Elekta, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Varian Medical Systems, Inc. | 1 | $13 |
| Olympus America Inc. | 1 | $13 |
How this compares
$762 in reported general payments places this provider in the 65th percentile of 121 radiation oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 23 | $1,126 |
| Mometasone Furoate | 49 | $885 |
| Oxycodone Hcl | 20 | $415 |
| Lidocaine Hcl ViscousLidocaine Hcl | 21 | $300 |
| Tamsulosin Hcl | 29 | $249 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fishersville
- Daniel KimFairfax$406K
- Samir KananiFairfax$90K
- David PenberthyCharlottesville$67K
- Gopal BajajFairfax$23K
- Ashish ChawlaFairfax$14K
- David BuckRoanoke$13K
- Kara RomanoCharlottesville$11K
- Gregory SibleyFairfax$10K
- Anthony CrimaldiCulpeper$10K
- Kevin ChoeFairfax$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.